Investor alert: khang & khang llp announces the filing of a securities class action lawsuit against insmed incorporated and reminds investors with losses to contact the firm

Irvine, calif.--(business wire)--khang & khang llp (the “firm”) announces that a class action lawsuit has been filed against insmed incorporated (“insmed” or the “company”) (nasdaq: insm). investors who purchased or otherwise acquired shares between march 18, 2013 and june 8, 2016 inclusive (the “class period”), are encouraged to contact the firm prior to the september 13, 2016 lead plaintiff motion deadline. if you purchased shares of insmed during the class period, please contact joon m. khang, esquire, of khang & khang, 18101 von karman avenue, 3rd floor, irvine, ca 92612, by telephone: (949) 419-3834, or by e-mail at joon@khanglaw.com. there has been no class certification in this case. until certification occurs, you are not represented by an attorney. you may choose to take no action and remain a passive class member. according to the complaint, insmed made false and/or misleading statements and/or failed to disclose that: the data on which insmed’s european marketing authorization application relied on for its lead product candidate for the treatment of ntm lung disease, arikayce, was not likely to support approval by the european medicines agency (“ema”); arikayce’s approval by the ema for the treatment of ntm lung disease and subsequent commercialization in europe were thus less likely than the company had led investors to believe; and as a result of the above, insmed’s public statements were materially false and misleading at all relevant times. if you wish to learn more about this lawsuit, or if you have any questions concerning this notice or your rights, please contact joon m. khang, a prominent litigator for almost two decades, by telephone: (949) 419-3834, or by e-mail at joon@khanglaw.com. this press release may constitute attorney advertising in some jurisdictions.
INSM Ratings Summary
INSM Quant Ranking